Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy
Basel, February 13, 2026 – Novartis today announced final results from the…
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
Basel, February 6, 2026 – Novartis today broke ground on a new,…
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjgrens disease
Basel, January 16, 2026 – Novartis today announced that the US Food and…
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
Basel, January 9, 2026 – Novartis, a leading global innovative medicines company,…
Capilea Mexico Unveils New Insights on Surge of US Patients Choosing Mexico for Hair Transplants
Mexico: The New Hub for US Hair Transplants December 26, 2025 10:00…
U.S. FDA Approves Agios AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and…
Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
The secondary analysis of the PACE trial highlights the value of counting…
Alvotech announces European launch of first-in-market biosimilar to Simponi (golimumab) globally by partner Advanz Pharma
Introduction of AVT05 supported by NHS England tender award in the United…
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced…
Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
In addition, the expansive elacestrant clinical development program updates reinforce its potential as…